Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3

Journal of Immunological Methods

Volumn 362, Issue 1-2, 2010, Pages 142-150

  Palarasah, Yaseelan ^a   Skjodt, Karsten ^a   Brandt, Jette ^a   Teisner, Børge ^a   Koch, Claus ^a   Vitved, Lars ^a   Skjoedt, Mikkel Ole ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

C3c; Complement; ELISA; Monoclonal antibody

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; FIBRINOGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSS REACTION; ELUTION; ENZYME IMMUNOASSAY; HEMOLYSIS; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOPRECIPITATION; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BLOOD DONORS; COMPLEMENT ACTIVATION; COMPLEMENT C3C; DENMARK; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED BALB C; SENSITIVITY AND SPECIFICITY;

EID: 77958507044     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.09.024     Document Type: Article

References (23)

1. Brandslund I., Siersted H.C., Svehag S.E., Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J. Immunol. Meth. 1981, 44:63.
2. Correale M., Brunetti N.D., De Gennaro L., Di Biase M. Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:272.
3. Dowling P., O'Driscoll L., Meleady P., Henry M., Roy S., Ballot J., Moriarty M., Crown J., Clynes M. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007, 28:4302.
4. Goldknopf I.L., Sheta E.A., Bryson J., Folsom B., Wilson C., Duty J., Yen A.A., Appel S.H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 342:1034.
5. Jack C., Ruffini F., Bar-Or A., Antel J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 2005, 81:363.
6. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495.
7. Li K., Sacks S.H., Zhou W. The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol. Immunol. 2007, 44:3866.
8. Ma J., Luo X., Wu Q., Chen Z., Kou L., Wang H. Circulation levels of acute phase proteins in patients with Takayasu arteritis. J. Vasc. Surg. 2010, 51:700.
9. Malmsten M., Schmidtchen A. Antimicrobial C3a-biology, biophysics, and evolution. Adv. Exp. Med. Biol. 2007, 598:141.
10. Mayer M. Complement and complement fixation. Experimental Immunochemistry 1961, 133. Charles C. Thomas, Springfield, Ill. E.A. Kabat, M.M. Mayer (Eds.).
11. Moller Rasmussen J., Teisner B., Jepsen H.H., Svehag S.E., Knudsen F., Kirstein H., Buhl M. Three cases of factor I deficiency: the effect of treatment with plasma. Clin. Exp. Immunol. 1988, 74:131.
12. Mollnes T.E., Lea T., Froland S.S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 1985, 22:197.
13. Myers G.L., Rifai N., Tracy R.P., Roberts W.L., Alexander R.W., Biasucci L.M., Catravas J.D., Cole T.G., Cooper G.R., Khan B.V., Kimberly M.M., Stein E.A., Taubert K.A., Warnick G.R., Waymack P.P. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the Laboratory Science Discussion Group. Circulation 2004, 110:e545.
14. Palarasah Y., Skjoedt M.O., Vitved L., Andersen T.E., Skjoedt K., Koch C. Sodium polyanethole sulfonate as an inhibitor of activation of complement function in blood culture systems. J. Clin. Microbiol. 2010, 48:908.
15. Pfeifer P.H., Kawahara M.S., Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin. Chem. 1999, 45:1190.
16. Pfeiffer N.E., Wylie D.E., Schuster S.M. Immunoaffinity chromatography utilizing monoclonal antibodies. Factors which influence antigen-binding capacity. J. Immunol. Meth. 1987, 97:1.
17. Rasmussen J.M., Teisner B., Brandslund I., Svehag S.E. A family with complement factor I deficiency. Scand. J. Immunol. 1986, 23:711.
18. Sahu A., Lambris J.D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 2001, 180:35.
19. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Meth. 2005, 296:187.
20. Tack B.F., Harrison R.A., Janatova J., Thomas M.L., Prahl J.W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl. Acad. Sci. USA 1980, 77:5764.
21. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058.
22. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 2001, 344:1140.
23. Walport M.J. Complement and systemic lupus erythematosus. Arthritis Res. 2002, 4(Suppl 3):S279.